Development of a Rat Model for Glioma-Related Epilepsy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Sep 2020
Historique:
received: 30 07 2020
revised: 18 09 2020
accepted: 21 09 2020
entrez: 26 9 2020
pubmed: 27 9 2020
medline: 24 2 2021
Statut: epublish

Résumé

Seizures are common in patients with high-grade gliomas (30-60%) and approximately 15-30% of glioblastoma (GB) patients develop drug-resistant epilepsy. Reliable animal models are needed to develop adequate treatments for glioma-related epilepsy. Therefore, fifteen rats were inoculated with F98 GB cells (GB group) and four rats with vehicle only (control group) in the right entorhinal cortex. MRI was performed to visualize tumor presence. A subset of seven GB and two control rats were implanted with recording electrodes to determine the occurrence of epileptic seizures with video-EEG recording over multiple days. In a subset of rats, tumor size and expression of tumor markers were investigated with histology or mRNA in situ hybridization. Tumors were visible on MRI six days post-inoculation. Time-dependent changes in tumor morphology and size were visible on MRI. Epileptic seizures were detected in all GB rats monitored with video-EEG. Twenty-one days after inoculation, rats were euthanized based on signs of discomfort and pain. This study describes, for the first time, reproducible tumor growth and spontaneous seizures upon inoculation of F98 cells in the rat entorhinal cortex. The development of this new model of GB-related epilepsy may be valuable to design new therapies against tumor growth and associated epileptic seizures.

Identifiants

pubmed: 32977526
pii: ijms21196999
doi: 10.3390/ijms21196999
pmc: PMC7582710
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1132820N
Organisme : UCB Pharma Belgium
ID : N.A.

Références

Brain Topogr. 2003 Winter;16(2):85-93
pubmed: 14977201
Neuro Oncol. 2012 Sep;14 Suppl 4:iv55-64
pubmed: 23095831
Epilepsy Res. 2020 Aug;164:106364
pubmed: 32497986
Front Neural Circuits. 2015 May 29;9:27
pubmed: 26074779
J Neurol. 2018 Jun;265(6):1432-1442
pubmed: 29687214
Front Cell Neurosci. 2014 Dec 12;8:418
pubmed: 25565956
Acta Neuropathol. 2004 Jan;107(1):1-7
pubmed: 13680280
Acta Neurochir (Wien). 2000;142(1):1-15
pubmed: 10664370
Epilepsy Behav. 2014 Sep;38:53-61
pubmed: 24894847
PLoS One. 2017 Jan 19;12(1):e0169292
pubmed: 28103256
Can J Neurol Sci. 2007 Aug;34(3):296-306
pubmed: 17803026
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
pubmed: 4110397
Epilepsia. 2006 Mar;47(3):661; discussion 661
pubmed: 16529640
Cancer Genet. 2012 Dec;205(12):613-21
pubmed: 23238284
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
Epilepsia. 2013 Dec;54 Suppl 9:12-7
pubmed: 24328866
Mol Neurobiol. 2018 Aug;55(8):6927-6938
pubmed: 29363044
Chin J Cancer. 2014 Jan;33(1):32-9
pubmed: 24384238
Nat Med. 2011 Sep 11;17(10):1269-74
pubmed: 21909104
Nature. 2019 Sep;573(7775):532-538
pubmed: 31534219
Curr Treat Options Neurol. 2015 Jun;17(6):351
pubmed: 25912245
Epilepsy Res. 2016 Oct;126:185-96
pubmed: 27513374
Nucl Med Biol. 2013 Aug;40(6):831-40
pubmed: 23915802
Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):82-88
pubmed: 30552865
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
J Neurooncol. 2009 Sep;94(3):299-312
pubmed: 19381449
Neurochem Int. 2013 Dec;63(7):696-701
pubmed: 23385090
Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8
pubmed: 27668386
Neurobiol Dis. 2006 Apr;22(1):64-75
pubmed: 16309916
Acta Neuropathol. 2017 Feb;133(2):263-282
pubmed: 28074274
J Neurooncol. 1998 Feb;36(3):231-42
pubmed: 9524101
J Neurotrauma. 2019 Jun;36(11):1890-1907
pubmed: 30543155
Curr Neuropharmacol. 2012 Jun;10(2):124-33
pubmed: 23204982
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Acta Oncol. 2009;48(7):955-63
pubmed: 19639468

Auteurs

Charlotte Bouckaert (C)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Charlotte Germonpré (C)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Jeroen Verhoeven (J)

Department of Pharmaceutical Analysis, Ghent University, 9000 Ghent, East Flanders, Belgium.

Seon-Ah Chong (SA)

Early Solutions, Neuroscience Therapeutic Area, UCB Pharma, 1420 Braine-l'Alleud, Brabant Wallon, Belgium.

Lucas Jacquin (L)

Early Solutions, Neuroscience Therapeutic Area, UCB Pharma, 1420 Braine-l'Alleud, Brabant Wallon, Belgium.

Georges Mairet-Coello (G)

Early Solutions, Neuroscience Therapeutic Area, UCB Pharma, 1420 Braine-l'Alleud, Brabant Wallon, Belgium.

Véronique Marie André (VM)

Early Solutions, Neuroscience Therapeutic Area, UCB Pharma, 1420 Braine-l'Alleud, Brabant Wallon, Belgium.

Karine Leclercq (K)

Early Solutions, Neuroscience Therapeutic Area, UCB Pharma, 1420 Braine-l'Alleud, Brabant Wallon, Belgium.

Christian Vanhove (C)

Department of Electronics and information systems, Ghent University Hospital, 9000 Ghent, East Flanders, Belgium.

Filip De Vos (F)

Department of Pharmaceutical Analysis, Ghent University, 9000 Ghent, East Flanders, Belgium.

Caroline Van den Broecke (C)

Department of Pharmaceutical Analysis, Ghent University, 9000 Ghent, East Flanders, Belgium.

Ingeborg Goethals (I)

Department of Diagnostic Sciences, Ghent University Hospital, 9000 Ghent, East Flanders, Belgium.

Benedicte Descamps (B)

Department of Electronics and information systems, Ghent University Hospital, 9000 Ghent, East Flanders, Belgium.

Sam Donche (S)

Department of Diagnostic Sciences, Ghent University Hospital, 9000 Ghent, East Flanders, Belgium.

Evelien Carrette (E)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Wytse Wadman (W)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Paul Boon (P)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Kristl Vonck (K)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Robrecht Raedt (R)

4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, East Flanders, Belgium.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH